Literature DB >> 24341905

Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients.

M S Pequet1, K E Holland, S Zhao, B A Drolet, S S Galbraith, D H Siegel, Y E Chiu.   

Abstract

BACKGROUND: Morphoea is a rare fibrosing disease of the skin and subcutaneous tissue with an unpredictable disease course, running the spectrum from mild skin involvement to severe disfigurement or extracutaneous complications.
OBJECTIVES: Our objective was to describe the natural history of paediatric morphoea and determine patient variables that were associated with severe disease. PATIENTS AND METHODS: We conducted a retrospective chart review of patients with morphoea seen in one paediatric hospital system. Information about demographics, clinical characteristics, disease course and treatment were collected. Statistical analysis was performed using appropriate univariate tests and a multivariable model.
RESULTS: One hundred and fourteen patients met study inclusion criteria. The female : male ratio was 2·6 : 1, and the median age of onset was 7 years old. There were 55 patients (48%) with linear morphoea, 38 patients (33%) with circumscribed morphoea, 12 patients (11%) with generalized morphoea, and nine patients (8%) with mixed morphoea. Neurological symptoms and joint involvement were present in 27 subjects (24%). Extracutaneous manifestations occurred in 38% of subjects with linear morphoea, compared with 15% with generalized morphoea and 3% with circumscribed morphoea (P = 0·0001). Thirty-six per cent of children with disease onset prior to 10 years of age and 5% of children with disease onset after 10 years of age had extracutaneous manifestations (P = 0·0002). Both linear morphoea and early-onset disease were significantly associated with extracutaneous involvement in a multivariable model.
CONCLUSIONS: Children with linear morphoea and disease onset before 10 years of age should be monitored closely for extracutaneous manifestations and need early treatment with systemic medications to prevent disease complications.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24341905      PMCID: PMC3989454          DOI: 10.1111/bjd.12758

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

1.  Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study.

Authors:  F Zulian; B H Athreya; R Laxer; A M Nelson; S K Feitosa de Oliveira; M G Punaro; R Cuttica; G C Higgins; L W A Van Suijlekom-Smit; T L Moore; C Lindsley; J Garcia-Consuegra; M O Esteves Hilário; L Lepore; C A Silva; C Machado; S M Garay; Y Uziel; G Martini; I Foeldvari; A Peserico; P Woo; J Harper
Journal:  Rheumatology (Oxford)       Date:  2005-12-20       Impact factor: 7.580

2.  Localized scleroderma in childhood is not just a skin disease.

Authors:  Francesco Zulian; Cristina Vallongo; Patricia Woo; Ricardo Russo; Nicolino Ruperto; John Harper; Graciela Espada; Fabrizia Corona; Masha Mukamel; Richard Vesely; Elzbieta Musiej-Nowakowska; Jeff Chaitow; Joan Ros; Maria T Apaz; Valeria Gerloni; Henryka Mazur-Zielinska; Susan Nielsen; Susanne Ullman; Gerd Horneff; Carine Wouters; Giorgia Martini; Rolando Cimaz; Ronald Laxer; Balu H Athreya
Journal:  Arthritis Rheum       Date:  2005-09

Review 3.  Localized scleroderma.

Authors:  Ronald M Laxer; Francesco Zulian
Journal:  Curr Opin Rheumatol       Date:  2006-11       Impact factor: 5.006

4.  Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children.

Authors:  L Weibel; M C Sampaio; M T Visentin; K J Howell; P Woo; J I Harper
Journal:  Br J Dermatol       Date:  2006-11       Impact factor: 9.302

5.  The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993.

Authors:  L S Peterson; A M Nelson; W P Su; T Mason; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

6.  Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.

Authors:  Francesco Zulian; Giorgia Martini; Cristina Vallongo; Fabio Vittadello; Fernanda Falcini; Annalisa Patrizi; Maria Alessio; Francesco La Torre; Rosa A Podda; Valeria Gerloni; Mario Cutrone; Anna Belloni-Fortina; Mauro Paradisi; Silvana Martino; Giorgio Perilongo
Journal:  Arthritis Rheum       Date:  2011-07

7.  A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea).

Authors:  Francesco Zulian; Cristina Vallongo; Annalisa Patrizi; Anna Belloni-Fortina; Mario Cutrone; Maria Alessio; Silvana Martino; Valeria Gerloni; Fabio Vittadello; Giorgia Martini
Journal:  J Am Acad Dermatol       Date:  2012-05-30       Impact factor: 11.527

8.  Misdiagnosis and delay in referral of children with localized scleroderma.

Authors:  L Weibel; B Laguda; D Atherton; J I Harper
Journal:  Br J Dermatol       Date:  2011-11-02       Impact factor: 9.302

9.  Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases.

Authors:  Justin J Leitenberger; Rachael L Cayce; Robert W Haley; Beverley Adams-Huet; Paul R Bergstresser; Heidi T Jacobe
Journal:  Arch Dermatol       Date:  2009-05

10.  Pediatric morphea (localized scleroderma): review of 136 patients.

Authors:  Stéphanie Christen-Zaech; Miriam D Hakim; F Sule Afsar; Amy S Paller
Journal:  J Am Acad Dermatol       Date:  2008-06-20       Impact factor: 11.527

View more
  5 in total

Review 1.  The Immunogenetics of Morphea and Lichen Sclerosus.

Authors:  Pooya Khan Mohammad Beigi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centre.

Authors:  Amanda M Saracino; Christina George; Svetlana I Nihtyanova; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2020-06-12

3.  Changes in Disease Activity and Damage Over Time in Patients With Morphea.

Authors:  Jack C O'Brien; Hugh Nymeyer; Allison Green; Heidi T Jacobe
Journal:  JAMA Dermatol       Date:  2020-05-01       Impact factor: 10.282

Review 4.  Immunopathogenesis of Pediatric Localized Scleroderma.

Authors:  Kathryn S Torok; Suzanne C Li; Heidi M Jacobe; Sarah F Taber; Anne M Stevens; Francesco Zulian; Theresa T Lu
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

5.  Application of an iPSC-Derived Organoid Model for Localized Scleroderma Therapy.

Authors:  Jie Ma; Wei Li; Ruiyuan Cao; Dunqin Gao; Qiyu Zhang; Xiao Li; Biyou Li; Luye Lv; Mansheng Li; Junyi Jiang; Yujie Wang; Jun Li; Zhihong Wu; Yunping Zhu; Wu Zhong; Shuyang Zhang; Ling Leng
Journal:  Adv Sci (Weinh)       Date:  2022-03-22       Impact factor: 17.521

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.